Trial reportJournal of neural transmission (Vienna, Austria : 1996)2008
Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type.
Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01600885 (The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
Who cites it
24 citing papers in PubMed.
- Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.Journal of child and adolescent psychopharmacology · 2015Trial
- Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.Journal of child and adolescent psychopharmacology · 2015Trial
- Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.Journal of the American Academy of Child and Adolescent Psychiatry · 2011Trial
- Review
- Review and Meta-analysis on the Impact of theBiological psychiatry global open science · 2022Article
- Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Subtype/Presentation: Research Progress and Translational Studies.Brain sciences · 2020Review
- PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.Pharmacogenetics and genomics · 2019Review
- Considerations for Implementing Precision Therapeutics for Children.Clinical and translational science · 2019Article
- Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy.Children (Basel, Switzerland) · 2019Article
- The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder.Psychiatry investigation · 2018Article
- A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.Journal of neural transmission (Vienna, Austria : 1996) · 2016Article
- Genetic Variations in Attention Deficit Hyperactivity Disorder Subtypes and Treatment Resistant Cases.Psychiatry investigation · 2016Article
- Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.The pharmacogenomics journal · 2014Article
- Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.British journal of clinical pharmacology · 2014Review
- Sequence analysis of the ADRA2A coding region in children affected by attention deficit hyperactivity disorder.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- The Brazilian contribution to Attention-Deficit/Hyperactivity Disorder molecular genetics in children and adolescents.Genetics and molecular biology · 2012Article
- Haplotype polymorphism in the alpha-2B-adrenergic receptor gene influences response inhibition in a large Chinese sample.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.European journal of clinical pharmacology · 2011Review
- Effects of the serotonin transporter (5-HTTLPR) and α2A-adrenoceptor (C-1291G) genotypes on substance use in children and adolescents: a longitudinal study.Psychopharmacology · 2011Article
- Adrenergic α2A receptor gene is not associated with methylphenidate response in adults with ADHD.European archives of psychiatry and clinical neuroscience · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An association between ADRA2A -1291 C > G polymorphism and response to methylphenidate in inattentive symptoms was previously suggested in children with ADHD. No investigation specifically assessed this association in ADHD-inattentive type (ADHD-I). In this naturalistic pharmacogenetic study, 59 subjects with ADHD-I from a non-referred sample were treated with short-acting methylphenidate and genotyped for ADRA2A -1291 C > G polymorphism. The primary outcome measure was the inattentive subscale of the SNAP-IV applied by a child psychiatrist blinded to genotype at baseline and first month of treatment. Children and adolescents with the G allele showed significantly lower inattentive scores with MPH treatment at the first month of treatment than subjects without the G allele (n = 59; F = 6.14; p = 0.016). We extended to ADHD-I previous findings suggesting the influence of the G allele at the ADRA2A -1291 C > G polymorphism on the improvement of inattentive symptoms with methylphenidate in children with all ADHD subtypes.
Indexed as
Identifiers
18200436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.